---
title: "DAJIAWEIKANG Q1 report: Net profit surged by 89.7%, driven by both professional pharmacies and the pharmaceutical industry"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284214762.md"
description: "On the evening of April 27th, DAJIAWEIKANG (301126) disclosed its Q1 2026 report. During the reporting period, the company achieved operating revenue of 1.384 billion yuan, a year-on-year increase of 6.49%; net profit attributable to the parent company was 5.965 million yuan, a year-on-year increase of"
datetime: "2026-04-27T12:23:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284214762.md)
  - [en](https://longbridge.com/en/news/284214762.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284214762.md)
generator: "portal-rs"
---

# DAJIAWEIKANG Q1 report: Net profit surged by 89.7%, driven by both professional pharmacies and the pharmaceutical industry

On the evening of April 27th, DAJIAWEIKANG (301126) disclosed its Q1 2026 report. During the reporting period, the company achieved operating revenue of 1.384 billion yuan, a year-on-year increase of 6.49%; net profit attributable to the parent company was 5.965 million yuan, a year-on-year increase of

### Related Stocks

- [301126.CN](https://longbridge.com/en/quote/301126.CN.md)

## Related News & Research

- [SPN: Q2 2026 saw record revenue growth, positive EBITDA, and improved margins amid ongoing macro headwinds](https://longbridge.com/en/news/297256815.md)
- [Livzon MABPharm wins China approval for Lecankitug psoriasis injection](https://longbridge.com/en/news/297167246.md)
- [VER: Q2 2026 delivered 6.5% like-for-like revenue growth and strong gross margin, with 2026 guidance reaffirmed](https://longbridge.com/en/news/297124510.md)
- [ByHeart Says FDA Confirms Review Of ByHeart's Root Cause Investigation And Action Plan](https://longbridge.com/en/news/297358769.md)
- [FDA allows marketing of Juul's new e-cigarettes and flavored pods](https://longbridge.com/en/news/297362439.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**